{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:53:55Z","timestamp":1770422035214,"version":"3.49.0"},"reference-count":130,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15128","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T10:48:38Z","timestamp":1748947718000},"page":"1-10","source":"Crossref","is-referenced-by-count":1,"title":["Development and challenges in the treatment of advanced gallbladder cancer (Review)"],"prefix":"10.3892","volume":"30","author":[{"given":"Bo","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"key20250703131010_b1-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00408-z","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"key20250703131010_b2-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","article-title":"Overview of current targeted therapy in gallbladder cancer","volume":"5","author":"Song","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"key20250703131010_b3-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/CM9.0000000000002759","article-title":"Advances in immunotherapy for biliary tract cancers","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"31","key":"key20250703131010_b4-ol-30-2-15128","article-title":"Gallbladder cancer: Epidemiology and genetic risk associations","volume":"8","author":"Schmidt","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"key20250703131010_b5-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1532835","DOI":"10.1155\/2017\/1532835","article-title":"Gallbladder carcinoma in the United States: A population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973\u20132013)","volume":"2017","author":"Lau","year":"2017","journal-title":"HPB Surg"},{"key":"key20250703131010_b6-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.suc.2018.12.008","article-title":"Gallbladder cancer: Diagnosis, surgical management, and adjuvant therapies","volume":"99","author":"Hickman","year":"2019","journal-title":"Surg Clin North Am"},{"key":"key20250703131010_b7-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"106234","DOI":"10.1016\/j.ijsu.2022.106234","article-title":"Current management of incidental gallbladder cancer: A review","volume":"98","author":"Feo","year":"2022","journal-title":"Int J Surg"},{"key":"key20250703131010_b8-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"104319","DOI":"10.1016\/j.ebiom.2022.104319","article-title":"Single-cell RNA sequencing highlights the functional role of human endogenous retroviruses in gallbladder cancer","volume":"85","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"key20250703131010_b9-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13046-019-1250-8","article-title":"PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR\/CCL2 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20250703131010_b10-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00117-021-00946-9","article-title":"Local and locoregional treatment of intrahepatic cholangiocarcinoma","volume":"62","author":"Wacker","year":"2022","journal-title":"Radiologe"},{"key":"key20250703131010_b11-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.surg.2023.01.019","article-title":"Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma","volume":"174","author":"Scott","year":"2023","journal-title":"Surgery"},{"key":"key20250703131010_b12-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"102258","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key20250703131010_b13-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.soc.2019.06.008","article-title":"Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma","volume":"28","author":"Mondaca","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"key20250703131010_b14-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20250703131010_b15-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jvir.2013.03.019","article-title":"Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy inpatients with unresectable intrahepatic cholangiocarcinoma","volume":"24","author":"Ray","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"key20250703131010_b16-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/den.13298","article-title":"Endoscopic radiofrequency biliary ablation treatment: A comprehensive review","volume":"31","author":"Larghi","year":"2019","journal-title":"Dig Endosc"},{"key":"key20250703131010_b17-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.brachy.2018.03.006","article-title":"Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter","volume":"17","author":"Deufel","year":"2018","journal-title":"Brachytherapy"},{"key":"key20250703131010_b18-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijsu.2018.04.048","article-title":"A meta-analysis of long-term survival outcomes between Surgical resection and radiofrequency ablation in patients with a single hepatocellular carcinoma <2 cm (BCLC very early stage)","volume":"56","author":"Yin","year":"2018","journal-title":"Int J Surg"},{"key":"key20250703131010_b19-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"604387","DOI":"10.3389\/fonc.2020.604387","article-title":"The evolving role of radiation therapy in the treatment of biliary tract cancer","volume":"10","author":"Gkika","year":"2020","journal-title":"Front Oncol"},{"key":"key20250703131010_b20-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","article-title":"Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: Single-institution analysis of outcome and toxicity","volume":"146","author":"Franzese","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20250703131010_b21-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.21873\/anticanres.13445","article-title":"Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study","volume":"39","author":"Bisello","year":"2019","journal-title":"Anticancer Res"},{"key":"key20250703131010_b22-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"110614","DOI":"10.1016\/j.radonc.2024.110614","article-title":"Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta-analysis","volume":"202","author":"Komiyama","year":"2025","journal-title":"Radiother Oncol"},{"key":"key20250703131010_b23-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/s12885-017-3788-1","article-title":"Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"17","author":"Gkika","year":"2017","journal-title":"BMC Cancer"},{"key":"key20250703131010_b24-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4251\/wjgo.v8.i3.240","article-title":"Endoscopic palliation of malignant biliary strictures","volume":"8","author":"Salgado","year":"2016","journal-title":"World J Gastrointest Oncol"},{"key":"key20250703131010_b25-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.3390\/jcm10143108","article-title":"Chemotherapy for biliary tract cancer in 2021","volume":"10","author":"Sasaki","year":"2021","journal-title":"J Clin Med"},{"key":"key20250703131010_b26-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13402-023-00799-5","article-title":"ELF3 promotes gemcitabine resistance through PKMYT1\/CDK1 signaling pathway in gallbladder cancer","volume":"46","author":"Yang","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"key":"key20250703131010_b27-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20250703131010_b28-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20250703131010_b29-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"key20250703131010_b30-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"key20250703131010_b31-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gallbladder cancer: A randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20250703131010_b32-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/COC.0000000000000989","article-title":"Update on chemoresistance mechanisms to first-line chemotherapy for gallbladder cancer and potential reversal strategies","volume":"46","author":"Lai","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"key20250703131010_b33-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20250703131010_b34-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomized, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20250703131010_b35-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/jjco\/hyv148","article-title":"FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients","volume":"46","author":"Dodagoudar","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"key20250703131010_b36-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20250703131010_b37-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1183619","DOI":"10.3389\/fphar.2023.1183619","article-title":"Gallbladder cancer: Current and future treatment options","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20250703131010_b38-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"100570","DOI":"10.1016\/j.esmoop.2022.100570","article-title":"How to read a next-generation sequencing report-what oncologists need to know","volume":"7","author":"Schmid","year":"2022","journal-title":"ESMO Open"},{"key":"key20250703131010_b39-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"a036798","DOI":"10.1101\/cshperspect.a036798","article-title":"Next-generation sequencing technologies","volume":"9","author":"McCombie","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key20250703131010_b40-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.3390\/cancers13215257","article-title":"Gallbladder cancer: Current insights in genetic alterations and their possible therapeutic implications","volume":"13","author":"Kuipers","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20250703131010_b41-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"key20250703131010_b42-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jmoldx.2015.12.003","article-title":"Somatic mutations of PI3K in early and advanced gallbladder cancer: Additional options for an orphan cancer","volume":"18","author":"Roa","year":"2016","journal-title":"J Mol Diagn"},{"key":"key20250703131010_b43-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s10620-016-4438-1","article-title":"Comparative analysis of mutational profile of sonic hedgehog gene in gallbladder cancer","volume":"62","author":"Dixit","year":"2017","journal-title":"Dig Dis Sci"},{"key":"key20250703131010_b44-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"604","DOI":"10.21037\/hbsn.2019.04.11","article-title":"Somatic genetic aberrations in gallbladder cancer: Comparison between Chinese and US patients","volume":"8","author":"Yang","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"key":"key20250703131010_b45-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1002\/cncr.32964","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"key":"key20250703131010_b46-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20250703131010_b47-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s10637-014-0096-3","article-title":"Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Investig","volume":"32","author":"Costello","year":"2014","journal-title":"New Drugs"},{"key":"key20250703131010_b48-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20250703131010_b49-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"key20250703131010_b50-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20250703131010_b51-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"key20250703131010_b52-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41418-022-00989-y","article-title":"Mutant p53: It's not all one and the same","volume":"29","author":"Kennedy","year":"2022","journal-title":"Cell Death Differ"},{"key":"key20250703131010_b53-ol-30-2-15128","first-page":"521","article-title":"p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions","volume":"43","author":"Ajiki","year":"1996","journal-title":"Hepatogastroenterology"},{"key":"key20250703131010_b54-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12967-022-03635-w","article-title":"Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53\/mTOR pathway","volume":"20","author":"Zhao","year":"2022","journal-title":"J Transl Med"},{"key":"key20250703131010_b55-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jhep.2020.11.033","article-title":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes","volume":"74","author":"Nepal","year":"2021","journal-title":"J Hepatol"},{"key":"key20250703131010_b56-ol-30-2-15128","first-page":"734","article-title":"Immunohistochemical markers in the study of gallbladder premalignant lesions and cancer","volume":"111","author":"Stancu","year":"2007","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"key20250703131010_b57-ol-30-2-15128","article-title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","author":"National Library of Medicine"},{"key":"key20250703131010_b58-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1101\/gad.347542.120","article-title":"Mutant p53 in cell-cell interactions","volume":"35","author":"Pilley","year":"2021","journal-title":"Genes Dev"},{"key":"key20250703131010_b59-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.3390\/ijms21103452","article-title":"p53: A guardian of immunity becomes its saboteur through mutation","volume":"21","author":"Agupitan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20250703131010_b60-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-024-00796-z","article-title":"p53 at the crossroads of tumor immunity","volume":"5","author":"Efe","year":"2024","journal-title":"Nat Cancer"},{"key":"key20250703131010_b61-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/1061186X.2021.1961791","article-title":"A bispecific decoy receptor VEGFR-EGFR\/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy","volume":"30","author":"Guo","year":"2022","journal-title":"J Drug Target"},{"key":"key20250703131010_b62-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.3892\/ol.2016.5287","article-title":"Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer","volume":"12","author":"Hung","year":"2016","journal-title":"Oncol Lett"},{"key":"key20250703131010_b63-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4103\/IJPM.IJPM_248_20","article-title":"Expression of VEGF-A, HER2\/neu, and KRAS in gall bladder carcinoma and their correlation with clinico-pathological parameters","volume":"64","author":"Singh","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"key20250703131010_b64-ol-30-2-15128","first-page":"713","article-title":"The effect and mechanism of vascular endothelial growth factor (VEGF) on tumor angiogenesis in gallbladder carcinoma","volume":"48","author":"Xu","year":"2019","journal-title":"Iran J Public Health"},{"key":"key20250703131010_b65-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/13543784.2021.1928636","article-title":"Targeted therapies for gallbladder cancer: An overview of agents in preclinical and clinical development","volume":"30","author":"De Lorenzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"key20250703131010_b66-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"15585","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: Implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20250703131010_b67-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20250703131010_b68-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"e30515","DOI":"10.1002\/jcb.30515","article-title":"Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment","volume":"125","author":"Ahamed","year":"2024","journal-title":"J Cell Biochem"},{"key":"key20250703131010_b69-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"567","DOI":"10.21873\/anticanres.14809","article-title":"Antiangiogenic tyrosine kinase inhibitors in metastatic colorectal cancer: Focusing on regorafenib","volume":"41","author":"Papadimitriou","year":"2021","journal-title":"Anticancer Res"},{"key":"key20250703131010_b70-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1038\/s41467-023-38430-8","article-title":"Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK\/MDM2\/p53 axis","volume":"14","author":"Yan","year":"2023","journal-title":"Nat Commun"},{"key":"key20250703131010_b71-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2021.1867537","article-title":"Regorafenib, an investigational agent for the treatment of cholangiocarcinoma","volume":"30","author":"Sahin","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"key20250703131010_b72-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signaling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20250703131010_b73-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","article-title":"Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis","volume":"68","author":"Li","year":"2019","journal-title":"Gut"},{"key":"key20250703131010_b74-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","article-title":"Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma","volume":"33","author":"Augustin","year":"2022","journal-title":"Ann Oncol"},{"key":"key20250703131010_b75-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"key":"key20250703131010_b76-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20250703131010_b77-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2022.11.005","article-title":"Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma","volume":"78","author":"Merters","year":"2023","journal-title":"J Hepatol"},{"key":"key20250703131010_b78-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"key20250703131010_b79-ol-30-2-15128","article-title":"Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy","author":"National Library of Medicine"},{"key":"key20250703131010_b80-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: Are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"key20250703131010_b81-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"108170","DOI":"10.1016\/j.pharmthera.2022.108170","article-title":"Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions","volume":"237","author":"Lavacchi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"key20250703131010_b82-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/liv.15773","article-title":"Exosome-derived miR-182-5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK\/SEMA5a\/PI3K pathway","volume":"44","author":"Wang","year":"2024","journal-title":"Liver Int"},{"key":"key20250703131010_b83-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2174\/1389450120666190618123846","article-title":"PI3K\/akt\/mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence Curr","volume":"20","author":"Narayanankutty","year":"2019","journal-title":"Drug Targets"},{"key":"key20250703131010_b84-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/carcin\/bgy038","article-title":"Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras\/MEK\/ERK and PI3K\/Akt\/mTOR pathways","volume":"39","author":"Rosenberg","year":"2018","journal-title":"Carcinogenesis"},{"key":"key20250703131010_b85-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/cas.14326","article-title":"Anthrax toxin receptor 1\/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K\/AKT\/mTOR signaling pathway","volume":"111","author":"Cai","year":"2020","journal-title":"Cancer Sci"},{"key":"key20250703131010_b86-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"19268","DOI":"10.1038\/s41598-021-98948-z","article-title":"Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"key20250703131010_b87-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"key20250703131010_b88-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","article-title":"ras genes","volume":"56","author":"Barbacid","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"key20250703131010_b89-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"8","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"key20250703131010_b90-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: From druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer"},{"key":"key20250703131010_b91-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"key":"key20250703131010_b92-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"key20250703131010_b93-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1158\/0008-5472.CAN-21-2176","article-title":"Concurrent activation of Kras and canonical Wnt signaling induces premalignant lesions that progress to extrahepatic biliary cancer in mice","volume":"82","author":"Nagao","year":"2022","journal-title":"Cancer Res"},{"key":"key20250703131010_b94-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"key20250703131010_b95-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"key20250703131010_b96-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"key":"key20250703131010_b97-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"key20250703131010_b98-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00432-022-04126-7","article-title":"Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: A case series and review of current literature","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20250703131010_b99-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1002\/cncr.35243","article-title":"SWOG 1609 cohort 48: Anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer","volume":"130","author":"Patel","year":"2024","journal-title":"Cancer"},{"key":"key20250703131010_b100-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.21037\/atm-21-4747","article-title":"Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer","volume":"9","author":"Zheng","year":"2021","journal-title":"Ann Transl Med"},{"key":"key20250703131010_b101-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"107870","DOI":"10.1016\/j.intimp.2021.107870","article-title":"PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia\/Lymphoma","volume":"98","author":"Jalili-Nik","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"key20250703131010_b102-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41417-022-00446-5","article-title":"Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis","volume":"29","author":"Zuo","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"key20250703131010_b103-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomized, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"key20250703131010_b104-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"key20250703131010_b105-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: Mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"key":"key20250703131010_b106-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"key20250703131010_b107-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1817931","DOI":"10.1155\/2020\/1817931","article-title":"Prognostic and clinicopathological significance of PD-L1 in patients with cholangiocarcinoma: A meta-analysis","volume":"2020","author":"Xie","year":"2020","journal-title":"Dis Markers"},{"key":"key20250703131010_b108-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small cell lung cancer: Current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"key20250703131010_b109-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/imt-2016-0150","article-title":"PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: Updated survival data","volume":"9","author":"Aguiar","year":"2017","journal-title":"Immunotherapy"},{"key":"key20250703131010_b110-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"key20250703131010_b111-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.annonc.2020.11.018","article-title":"Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy","volume":"32","author":"Sznol","year":"2021","journal-title":"Ann Oncol"},{"key":"key20250703131010_b112-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20250703131010_b113-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"key20250703131010_b114-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"key20250703131010_b115-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"key20250703131010_b116-ol-30-2-15128","article-title":"Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma","author":"National Library of Medicine"},{"key":"key20250703131010_b117-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20250703131010_b118-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"key20250703131010_b119-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20250703131010_b120-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"key20250703131010_b121-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"key20250703131010_b122-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14712598.2020.1815704","article-title":"Recent developments of RNA-based vaccines in cancer immunotherapy","volume":"21","author":"Faghfuri","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"key20250703131010_b123-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"11256","DOI":"10.3390\/ijms252011256","article-title":"Cancer vaccines: Recent insights and future directions","volume":"25","author":"Malacopol","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20250703131010_b124-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"key20250703131010_b125-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.gie.2023.06.054","article-title":"EUS-guided gallbladder drainage using a lumen-apposing metal stent as rescue treatment for malignant distal biliary obstruction: A large multicenter experience","volume":"98","author":"Binda","year":"2023","journal-title":"Gastrointest Endosc"},{"key":"key20250703131010_b126-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0012","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20250703131010_b127-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1002\/1878-0261.13278","article-title":"Palliative oncology and palliative care","volume":"16","author":"Strang","year":"2022","journal-title":"Mol Oncol"},{"key":"key20250703131010_b128-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1177\/0193945919853162","article-title":"Evolution and conceptual foundations of nonhospice palliative care","volume":"41","author":"Beasley","year":"2019","journal-title":"West J Nurs Res"},{"key":"key20250703131010_b129-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1049909117723860","article-title":"Palliative care gaps in providing psychological treatment: A review of the current state of research in multidisciplinary palliative care","volume":"35","author":"Kozlov","year":"2018","journal-title":"Am J Hosp Palliat Care"},{"key":"key20250703131010_b130-ol-30-2-15128","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/pon.4735","article-title":"Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed-methods study","volume":"27","author":"Tondorf","year":"2018","journal-title":"Psychooncology"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:10:19Z","timestamp":1751537419000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":130,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15128","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}